Sector News

Merck to buy biopharmaceutical firm ArQule for $2.7bn

December 11, 2019
Life sciences

Merck has signed an agreement to acquire biopharmaceutical company ArQule for a total equity value of around $2.7bn.

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases.

The company’s clinical-stage pipeline consists of four drug candidates, including ARQ 531, ARQ 751, miransertib (ARQ 092) and derazantinib.

ArQule CEO Paolo Pucci said: “We are proud that Merck has recognized the contributions that ArQule, together with its scientific collaborators, has made to the field of precision medicine in oncology with ARQ 531 for the treatment of B-cell malignancies and with the rest of our clinical-stage pipeline.”

The ARQ 531 is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor, which is currently in a phase 2 dose expansion trial to treat B-cell malignancies. It is a selective, reversible inhibitor that inhibits both wild-type BTK and the C481S mutant form of the enzyme, which is generally associated with resistance to other BTK inhibitors.

The ARQ 751 is a next-generation potent and selective AKT inhibitor, which is under phase 1 study to treat patients with solid tumours with AKT1 and PI3K mutations.

Miransertib (ARQ 092) is a potent and selective inhibitor of the AKT serine/threonine kinase that is currently under a registrational trial with cohorts in Proteus syndrome and PROS.

Derazantinib is a multi-kinase inhibitor designed to selectively block the fibroblast growth factor receptor (FGFR) family. It is currently under registrational trial for iCCA in collaboration with Basilea and Sinovant.

As per terms of the deal, Merck’s subsidiary will commence a tender offer to purchase all outstanding shares of ArQule. Merck’s acquisition subsidiary will be merged into ArQule, upon the successful completion of the tender offer

Subject to certain conditions, the deal is expected to complete early in the first quarter of 2020.

On the transaction, BofA Securities served as financial advisor to Merck, while Covington & Burling as its legal advisor. Centerview Partners served as exclusive financial advisor to ArQule, while Skadden, Arps, Slate, Meagher & Flom as its legal advisor.

Merck Research Laboratories president Dr Roger Perlmutter said: “ArQule’s focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties.”

In November, COI Pharmaceuticals announced that Merck agreed to acquire Calporta Therapeutics in a deal valued at around $576m.

Source: PBR

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend